Thirteen outpatients with chronic but stable schizophrenia received donepezil and placebo augmentation of their maintenance antipsychotic medication regimen. Each subject received in a randomized, counterbalanced order 1) donepezil 5 mg for 6 weeks then donepezil 10 mg for six weeks and 2) placebo donepezil for 12 weeks. Serial ratings of the Positive and Negative Symptom Scale (PANSS) [Kay, S.R., Fiszbein, A., Opler, L.A., 1987. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophrenia Bulletin 13(2): 261-276] were performed by a trained rater blind to the donepezil order and condition: at baseline, 12 weeks and 24 weeks. On donepezil as compared to baseline or placebo, there was a significant improvement in PANSS negative scores (p = .018, n = 13). These results are discussed with respect to other studies using cholinesterase inhibitors as an augmentation strategy in schizophrenia.
Bibliographical noteFunding Information:
Dr. Risch is currently or has been in the past on the speakers’ bureau, a consultant, or has received research funds from the following sources: Abbott, Astra Zeneca, Bristol-Myers Squibb, Eli Lilly, Forest, GlaxoSmithKline, Janssen, Novartis, Pfizer, and the NIMH. Dr. McGurk is on the speakers’ bureau for Janssen and Pfizer. Dr. DeVane is on the speakers’ bureau, a consultant, or has received research funding from Theracos, Inc., Novodel Inc., Quintiles Inc., GlaxoSmithKline, Janssen, Eli Lilly, NIDA and NIMH. Dr. Markowitz is currently or has been in the past on the speakers’ bureau, a consultant, or has received research funding from Novartis, Janssen, Eli Lilly, and NICHD. Dr. Nahas is currently or has been in the past on the speakers’ bureau, a consultant, or has received research funds from the following sources: Neuronetics Inc, Cyberonics Inc, Medtronic Inc. Neuropace, Integra, Eli Lilly, Avenir Pharmaceutical, Aventis Pharmaceutical, Astra Zeneca in addition to funding from the NIMH and NARSAD.
This work was supported, in part, by unrestricted educational grants from Eli Lilly and Company, and from Janssen Pharmaceutical Company.
- Cholinesterase Inhibitors
- Pharmacological Augmentation